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Background and Methods: We analyzed the late outcome of
long-term survivors of allogeneic stem cell transplantation (allo-
SCT) treated by the Leukemia/Bone Marrow Transplant Program
of British Columbia. Results: We reviewed the charts of 430
patients (pts) who received allo-SCT between 1981 and 2002 for
hematologic malignancies and who were free of their primary
disease for at least two years after transplant. Late recurrent pri-
mary malignancy was found in 13% (57 pts) of allo-SCT recipients
and was the primary cause of late death. 31 (7%) allo-SCT recip-
ients died of non-relapse causes at a median of 5.5 year (range 2 to
15.6) post allo-SCT. Non relapse causes of death were GVHD (11
pts), second cancer (8), coronary disease (3), infection (2), miscel-
laneous (5), and unknown (2). 342 non relapse long-term allo-SCT
survivors were evaluated for late complications. Median follow-up
for the survivors was 8 (range 2 to 23) years. Chronic graft versus
host disease (cGVHD) was diagnosed in 205 (60%) survivors with
more than 50% of pts still having symptoms of cGVHD at last
follow-up. Cardiovascular complications in survivors included hy-
pertension (21%), coronary disease (3%) and myocardial infarction
(2%). Renal failure was diagnosed in 64 (17%) survivors; it resolved
over time in 17 pts; 6 pts needed dialysis. Endocrine complications
seen in survivors included dyslipidemia (10%), hypothyroidism
(9%), diabetes (7%), osteopenia/osteoporosis (25%), hypogonad-
ism in females (76%) and hypogonadism in males (7%). Depres-
sion was reported in 41 (11%) survivors, and 2 pts attempted
suicide. Cognitive impairment and other psychiatric problems
were identiﬁed in 2% and 3% respectively. Sexual dysfunction was
reported in 6% of survivors. Conclusions: In patients who receive
allo-SCT as treatment for hematologic malignancy and who are
disease-free 2 years post transplant, probability of durable remis-
sion is high with acceptable but deﬁnite late toxicity. The occur-
rence of late events necessitates lifelong medical surveillance.
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The development of second solid cancers in recipients of hema-
topoietic stem cell transplants (SCT) represents a serious compli-
cation among long term survivors. To assess the incidence and
associated risk factors for second solid cancers following allogeneic
SCT, we performed a retrospective analysis of 926 consecutive
patients (pts) who underwent an allogeneic SCT between January
1985 and December 2003. Primary diagnoses were AML (235),
ALL (103), CML (216), lymphoproliferative disorders (150), MDS
(96), MM (80), or other (46). Median age at SCT was 39 years
(range 12–65) and median time from diagnosis to SCT was 5.1
months (range 0.2–345). Six hundred forty pts had a sibling donor
and 286 had an unrelated donor. Stem cell source was bone mar-
row (810), peripheral blood (109), or both (7). Conditioning reg-
imens were: TBI-based (488), BuCy other (414), other (24). The
graft was T cell depleted in 43 pts. With a median follow-up of
22.2 months post SCT (range 0.07–230.5) for all 926 pts and 84.2
months (range 8.4–230.5) for surviving pts, 30 solid malignancies
have occurred in 28 pts at a median of 81.4 months post SCT
(range 1.4–207.5). These second tumors involved skin (8 basal cell
carcinoma, 4 invasive squamous cell carcinoma), lung (5), oral
cavity (4), colon (2), bladder (2) breast (1), kidney (1), parotid gland
(1), vulva-in situ (1), and primary unknown (1). Of the 28 pts, 6
died from the second cancer at a median of 6.1 months (range
0.9–36) following the diagnosis. The 10-year cumulative incidence
of all second solid cancers was 3.1% (95% CI 2–5%). Compared to
age and gender adjusted cancer rates in the general population of
BC, the relative risk (RR) of developing a second solid cancer after
allografting excluding nonmelanoma skin cancer was 1.85 (95% CI
1.04–3.06), P  .019. In multivariate analysis, signiﬁcant risk
factors were recipient age at SCT 	 40 years (RR 4.8), P .01 and
donor gender [female donor/male recipient (RR 5.4), female do-
nor/female recipient (RR 2.3)] P .002. We conclude that alloge-
neic SCT recipients are at an increased risk of developing a second
solid cancer compared to the general population, particularly if the
recipient is 	40 years old at the time of allografting. It is also
apparent that male recipients of a female graft have a higher risk of
second solid cancers. Longer follow-up is needed to more fully
assess the incidence and risk factors for second solid tumors post-
transplant due to their long latency period.
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Bone marrow transplantation (BMT) is the treatment of choice
for many patients with malignant and non-malignant diseases. As
the survival of these patients increases, long term complications
such as osteoporosis should be considered, because it associates
with morbidity and mortality of the patients directly. We have
prospectively investigated 63 patients undergoing BMT for acute
and chronic leukemia and lymphoma. Bone mineral density (BMD)
was measured with dual X-ray absorptiometry before BMT, 6 and
12 months later also. Osteocalsin and bone alkaline phosphatase as
markers of bone formation and c-terminal telopeptides of type 1
collagen as a marker of bone resorption were assessed. Moreover,
serum concentration of calcium, phosphorous, vitamin D, PTH,
and sex hormones (FSH, LH, testostorone, estradiol) were mea-
sured. There was signiﬁcant decrease in BMD of femoral neck 6
months after BMT (0.06 gr/cm2 in allogenic and 0.04 gr/cm2 in
autologous) but no considerable changes were seen in lumbar
vertebrae. Also, more decrease in bone loss between sixth and
twelfth months was not observed. After one year the rate of os-
teopenia and osteoporosis increased in allogenic and autologous
BMT 10% and 20%, respectively. There was signiﬁcant increase in
the marker of bone resorption but bone formation markers not
only decreased but also increased at the same time. No distinct
difference was observed in serum biochemical turnover markers
between males and females, or between autologous and allogenic
BMT patients. Seventy-six and 90% of the women went into
menopausal state in 6 and 12 months after BMT, respectively, but
male sex hormones did not change considerably. In conclusion, the
risk of bone loss in both allogenic and autologous BMT is higher
in femoral neck rather than lumbar vertebrae and it occurred
mainly in the ﬁrst 6 months after BMT. Preventional and clinical
procedures should be considered.
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Introduction: Despite recent advances in diagnosis and treat-
ment, invasive Aspergillosis (IA) remains a signiﬁcant threat to
hematopoietic stem cell transplant (HSCT) patients. It is estimated
that over 90% of undiagnosed and untreated cases of IA result in
death. Because anti-fungal drug susceptibility varies between the
Aspergillus species, species-speciﬁc identiﬁcation improves the IA
disease management signiﬁcantly. Recently, real time PCR assays
have been reported in diagnosing IA, however, these assays lack
speciﬁcity. Using scorpion technology, we developed a rapid, sen-
sitive, and quantitative real time PCR assay for species-speciﬁc
identiﬁcation of Aspergillus infections that does not cross-react with
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